A number of research firms have changed their ratings and price targets for Global Blood Therapeutics (NASDAQ: GBT):

  • 12/6/2017 – Global Blood Therapeutics was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. “
  • 12/4/2017 – Global Blood Therapeutics had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $73.00 price target on the stock.
  • 12/1/2017 – Global Blood Therapeutics was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 12/1/2017 – Global Blood Therapeutics is now covered by analysts at HC Wainwright. They set a “buy” rating and a $73.00 price target on the stock.
  • 11/13/2017 – Global Blood Therapeutics was given a new $53.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 11/9/2017 – Global Blood Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $83.00 price target on the stock. They wrote, “GBT reported Q3 earnings last week and provided a brief summary of their progress.””
  • 11/7/2017 – Global Blood Therapeutics was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. “
  • 11/6/2017 – Global Blood Therapeutics had its price target raised by analysts at SunTrust Banks, Inc. to $67.00. They now have a “buy” rating on the stock.
  • 11/1/2017 – Global Blood Therapeutics was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating.
  • 10/30/2017 – Global Blood Therapeutics was given a new $53.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 10/24/2017 – Global Blood Therapeutics was given a new $51.00 price target on by analysts at Needham & Company LLC. They now have a “buy” rating on the stock.
  • 10/23/2017 – Global Blood Therapeutics had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co.
  • 10/23/2017 – Global Blood Therapeutics was given a new $53.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 10/18/2017 – Global Blood Therapeutics was given a new $51.00 price target on by analysts at Needham & Company LLC. They now have a “buy” rating on the stock.
  • 10/16/2017 – Global Blood Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. “
  • 10/11/2017 – Global Blood Therapeutics was given a new $53.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 10/10/2017 – Global Blood Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $36.00 price target on the stock. According to Zacks, “Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. “

Shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) traded up $3.55 during trading on Thursday, hitting $43.85. The stock had a trading volume of 1,371,626 shares, compared to its average volume of 988,862. Global Blood Therapeutics, Inc. has a 12 month low of $13.35 and a 12 month high of $44.30.

Global Blood Therapeutics (NASDAQ:GBT) last issued its quarterly earnings results on Thursday, November 2nd. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same quarter in the prior year, the company posted ($0.58) earnings per share. sell-side analysts anticipate that Global Blood Therapeutics, Inc. will post -2.55 EPS for the current year.

In other news, VP Peter Radovich sold 12,500 shares of the business’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the sale, the vice president now directly owns 2,684 shares in the company, valued at $93,940. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Charles J. Homcy sold 70,000 shares of Global Blood Therapeutics stock in a transaction dated Friday, October 27th. The shares were sold at an average price of $33.97, for a total value of $2,377,900.00. Following the completion of the sale, the director now directly owns 83,328 shares in the company, valued at approximately $2,830,652.16. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 88,500 shares of company stock worth $3,003,350. Corporate insiders own 5.30% of the company’s stock.

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Receive News & Ratings for Global Blood Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.